Xinmin Z. Yu
38 Guangji Road
Hangzhou, 310022, China
Hangzhou, 310022, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 81 publications
Efficacy and safety of first-line osimertinib in Chinese patients with EGFR-mutated advanced non-small cell lung cancer: a prospective, multicenter, non-interventional study (FLOURISH).
Journal: Cancer biology & medicine
Published: May 22, 2026
AdvanTIG-302: Phase 3 Study of Ociperlimab (Anti-TIGIT) + Tislelizumab (Anti-PD-1) Versus Pembrolizumab in Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer With PD-L1 ≥50.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: February 22, 2026
Deulorlatinib (TGRX-326) in ALK Gene Fusion Positive NSCLC After Failure of Second-Generation Inhibitors: A Single-Arm, Multicenter, Phase 2 Trial.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: February 09, 2026
Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial.
Journal: Nature medicine
Published: January 29, 2026
Prognostic associations between patient-reported outcomes and overall survival among patients with advanced squamous non-small cell lung cancer: results from the RATIONALE-307 trial.
Journal: Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
Published: December 30, 2025
First-Line Tislelizumab Plus Chemotherapy for Advanced or Metastatic Squamous Non-Small Cell Lung Cancer: 4-Year Long-Term Follow-Up from RATIONALE-307.
Journal: Oncology and therapy
Published: October 03, 2025
Rapidly dissolving microneedle patch embedded with long-acting microspheres for sustained release of goserelin.
Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: August 24, 2025
Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial.
Journal: The Lancet. Oncology
Published: August 01, 2025
High-Dose Aumolertinib for Untreated EGFR-Variant Non-Small Cell Lung Cancer With Brain Metastases: The ACHIEVE Phase 2 Nonrandomized Clinical Trial.
Journal: JAMA oncology
Published: June 26, 2025
First-Line Tislelizumab Plus Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer: PD-L1 ≥ 50% Subgroup Analysis from the RATIONALE-304 Trial.
Journal: Oncology and therapy
Published: June 18, 2025
Last Updated: 09/26/2026